USD 238.56
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| LH | -0.1 | 3.1 | 3.3 | 10.9 | 10.6 | 7.0 | 2.2 | 56.9 | 136.9 | 1039.3 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | LH |
| name | Laboratory Corporation of America Holdings |
| price | 238.56 |
| changes percentage | -0.088 |
| change | -0.21 |
| day low | 236.95 |
| day high | 242.74 |
| year high | 247.99 |
| year low | 191.97 |
| market cap | 19952991408 |
| price avg 50 | 234.771 |
| price avg 200 | 218.4031 |
| exchange | NYSE |
| volume | 538352 |
| avg volume | 613855 |
| open | 239.33 |
| previous close | 238.77 |
| eps | 5.28 |
| pe | 45.18 |
| earnings announcement | 2025-02-06T13:30:00.000+0000 |
| shares outstanding | 83639300 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000920148 | |||
| revenue | 12161600000 | 14876800000 | -18.25 |
| gross profit | 3364900000 | 4385100000 | -23.27 |
| gross profit ratio | 0.28 | 0.29 | -6.13 |
| research and development expenses | 2000000 | 0 | NaN |
| operating expenses | 2639300000 | 2255900000 | 17.00 |
| interest income | 0 | 8900000 | -100.00 |
| interest expense | 199600000 | 180300000 | 10.70 |
| ebitda | 1349400000 | 1954400000 | -30.96 |
| ebitdaratio | 0.11 | 0.18 | -39.83 |
| operating income | 725600000 | 1773900000 | -59.10 |
| operating income ratio | 0.06 | 0.12 | -49.96 |
| net income | 418000000 | 1279100000 | -67.32 |
| net income ratio | 0.03 | 0.09 | -60.02 |
| eps | 4.8 | 14.04 | -65.81 |
Revenue Growth: revenue decreased to 12,162 million in 2023 from 14,877 million in 2022 representing a change of -18.25%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 3,365 million in 2023 from 4,385 million in 2022 representing a change of -23.27%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 2,639 million in 2023 from 2,256 million in 2022 representing a change of 17.0%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 1,349 million in 2023 from 1,954 million in 2022 representing a change of -30.96%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Earnings per Share (EPS): EPS increased to 4.8 in 2023 from 4.8 in 2022 representing a change of -65.81%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 2 million in 2023 from 0 million in 2022 representing a change of nan%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Operating Income: Operating income increased to 726 million in 2023 from 1,774 million in 2022 representing a change of -59.1%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to 418 million in 2023 from 1,279 million in 2022 representing a change of -67.32%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000920148 | |||
| revenue | 3282000000 | 3220900000 | 1.90 |
| gross profit | 904400000 | 864200000 | 4.65 |
| gross profit ratio | 0.28 | 0.27 | 2.70 |
| research and development expenses | 0 | 0 | NaN |
| operating expenses | 650300000 | 557800000 | 16.58 |
| interest income | 0 | 0 | NaN |
| interest expense | 50400000 | 47600000 | 5.88 |
| ebitda | 422500000 | 463300000 | -8.81 |
| ebitdaratio | 0.13 | 0.14 | -10.50 |
| operating income | 254100000 | 306400000 | -17.07 |
| operating income ratio | 0.08 | 0.1 | -18.61 |
| net income | 169300000 | 205300000 | -17.54 |
| net income ratio | 0.05 | 0.06 | -19.07 |
| eps | 2.02 | 2.44 | -17.21 |
Revenue Growth: revenue increased to 3,282 million in 2024Q2 from 3,221 million in 2024Q1 representing a change of 1.9%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 904 million in 2024Q2 from 864 million in 2024Q1 representing a change of 4.65%. This indicates a sales profitability growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses increased to 650 million in 2024Q2 from 558 million in 2024Q1 representing a change of 16.58%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 422 million in 2024Q2 from 463 million in 2024Q1 representing a change of -8.81%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to 254 million in 2024Q2 from 306 million in 2024Q1 representing a change of -17.07%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to 169 million in 2024Q2 from 205 million in 2024Q1 representing a change of -17.54%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to 2.02 in 2024Q2 from 2.02 in 2024Q1 representing a change of -17.21%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000920148 | |||
| total assets | 16725099999 | 20155100000 | -17.02 |
| total liabilities | 8834600000 | 10058500000 | -12.17 |
| total equity | 7890500000 | 10115500000 | -22.00 |
| cash and cash equivalents | 536799999 | 430000000 | 24.84 |
| short term investments | 0 | 0 | NaN |
| long term investments | 26900000 | 65700000 | -59.06 |
| total current assets | 3765400000 | 4625000000 | -18.59 |
| total non current assets | 12959699999 | 15530100000 | -16.55 |
| total current liabilities | 3225200000 | 3078500000 | 4.77 |
| total non current liabilities | 5609400000 | 6980000000 | -19.64 |
| common stock | 7700000 | 8100000 | -4.94 |
| retained earnings | 7888200000 | 10581700000 | -25.45 |
| total debt | 5954200000 | 6294900000 | -5.41 |
Total Assets: Total Assets decreased to 16,725 million in 2023 from 20,155 million in 2022 representing a change of -17.02%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 7,890 million in 2023 from 10,116 million in 2022 representing a change of -22.0%. This indicates a decrease in shareholders' equity.
Total Current Assets: Total Current Assets decreased to 3,765 million in 2023 from 4,625 million in 2022 representing a change of -18.59%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 3,225 million in 2023 from 3,078 million in 2022 representing a change of 4.77%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 8 in 2023 from 8 in 2022 representing a change of -4.94%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to 7,888 million in 2023 from 10,582 million in 2022 representing a change of -25.45%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 8,835 million in 2023 from 10,058 million in 2022 representing a change of -12.17%. This indicates a decrease in overall liabilities.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 537 million in 2023 from 430 million in 2022 representing a change of 24.84%. This indicates an increase in available liquid assets.
Total Debt: Total Debt decreased to 5,954 million in 2023 from 6,295 million in 2022 representing a change of -5.41%. This indicates a reduction in overall debt burden.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000920148 | |||
| total assets | 18612500000 | 16712300000 | 11.37 |
| total liabilities | 10427100000 | 8691500000 | 19.97 |
| total equity | 8185400000 | 8020800000 | 2.05 |
| cash and cash equivalents | 1517300000 | 265100000 | 472.35 |
| short term investments | 0 | 0 | NaN |
| long term investments | 16900000 | 17500000 | -3.43 |
| total current assets | 4909900000 | 3571300000 | 37.48 |
| total non current assets | 13702600000 | 13141000000 | 4.27 |
| total current liabilities | 3412000000 | 4064700000 | -16.06 |
| total non current liabilities | 7015100000 | 4626800000 | 51.62 |
| common stock | 7600000 | 7700000 | -1.30 |
| retained earnings | 8275800000 | 8177600000 | 1.20 |
| total debt | 7719100000 | 5975100000 | 29.19 |
Total Assets: Total Assets increased to 18,612 million in 2024Q2 from 16,712 million in 2024Q1 representing a change of 11.37%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 8,185 million in 2024Q2 from 8,021 million in 2024Q1 representing a change of 2.05%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 1,517 million in 2024Q2 from 265 million in 2024Q1 representing a change of 472.35%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 4,910 million in 2024Q2 from 3,571 million in 2024Q1 representing a change of 37.48%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 3,412 million in 2024Q2 from 4,065 million in 2024Q1 representing a change of -16.06%. This indicates a lower short-term debt burden.
Retained Earnings: Retained Earnings increased to 8,276 million in 2024Q2 from 8,178 million in 2024Q1 representing a change of 1.2%. This indicates an accumulated profits.
Total Liabilities: Total Liabilities increased to 10,427 million in 2024Q2 from 8,692 million in 2024Q1 representing a change of 19.97%. This indicates an increase in overall liabilities.
Common Stock: Common Stock decreased to 8 in 2024Q2 from 8 in 2024Q1 representing a change of -1.3%. This indicates a decrease in ownership interest.
Total Debt: Total Debt increased to 7,719 million in 2024Q2 from 5,975 million in 2024Q1 representing a change of 29.19%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0000920148 | |||
| net change in cash | 216199999 | -1042700000 | 120.73 |
| operating cash flow | 1327700000 | 1955900000 | -32.12 |
| free cash flow | 874100000 | 1474000000 | -40.70 |
| capital expenditure | -453600000 | -481900000 | 5.87 |
| depreciation and amortization | 577300000 | 633900000 | -8.93 |
| deferred income tax | -78100000 | 18300000 | -526.78 |
| stock based compensation | 128699999 | 116800000 | 10.19 |
| accounts payables | -42400000 | 307100000 | -113.81 |
| inventory | -700000 | -45500000 | 98.46 |
| acquisitions net | -671500000 | -1162400000 | 42.23 |
| investments in property plant and equipment | -453600000 | -481900000 | 5.87 |
| net cash used for investing activites | -1171500000 | -1652200000 | 29.09 |
| debt repayment | -300000000 | 0 | NaN |
| common stock issued | 0 | 50600000 | -100.00 |
| common stock repurchased | -1000000000 | -1100000000 | 9.09 |
| dividends paid | -254000000 | -195200000 | -30.12 |
| net cash used provided by financing activities | -59300000 | -1322200000 | 95.52 |
| cash at end of period | 536799999 | 430000000 | 24.84 |
| accounts receivables | -75300000 | 15900000 | -573.58 |
| cash at beginning of period | 320600000 | 1472700000 | -78.23 |
Net Change in Cash: Net Change in Cash increased to 216 million in 2023 from -1,043 million in 2022 representing a change of 120.73%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables decreased to 42 million in 2023 from 307 million in 2022 representing a change of -113.81%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to -75 million in 2023 from 16 million in 2022 representing a change of -573.58%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
Operating Cash Flow: Operating Cash Flow decreased to 1,328 million in 2023 from 1,956 million in 2022 representing a change of -32.12%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 874 million in 2023 from 1,474 million in 2022 representing a change of -40.7%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -454 million in 2023 from -482 million in 2022 representing a change of 5.87%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Stock-Based Compensation: Stock-Based Compensation increased to 129 million in 2023 from 117 million in 2022 representing a change of 10.19%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Dividends Paid: Dividends Paid decreased to -254 million in 2023 from -195 million in 2022 representing a change of -30.12%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
| 2024Q2 | 2024Q1 | Q/Q change % | |
|---|---|---|---|
| 0000920148 | |||
| operating cash flow | 277300000 | 561100000 | -50.58 |
| free cash flow | 161500000 | 432900001 | -62.69 |
| capital expenditure | -115800000 | -128199999 | 9.67 |
| depreciation and amortization | 161500000 | 156900000 | 2.93 |
| deferred income tax | -19500000 | -19600000 | 0.51 |
| stock based compensation | 27000000 | 30800000 | -12.34 |
| accounts receivables | 45000000 | -42200000 | 206.64 |
| accounts payables | -86500000 | 69400000 | -224.64 |
| inventory | -25700000 | 28300000 | -190.81 |
| acquisitions net | -463700000 | -33800000 | -1271.89 |
| investments in property plant and equipment | -115800000 | -128199999 | 9.67 |
| net cash used for investing activites | -579100000 | -185000000 | -213.03 |
| debt repayment | 1380200000 | -22600000 | 6207.08 |
| common stock issued | 0 | -23100000 | 100.00 |
| common stock repurchased | -75000000 | -100000000 | 25.00 |
| dividends paid | -60500000 | -60400000 | -0.17 |
| net cash used provided by financing activities | 1548300000 | -210000000 | 837.29 |
| net change in cash | 1252200000 | 165800000 | 655.25 |
| cash at end of period | 1517300000 | 265100000 | 472.35 |
| cash at beginning of period | 265100000 | 99300000 | 166.97 |
Net Change in Cash: Net Change in Cash increased to 1,252 million in 2024Q2 from 166 million in 2024Q1 representing a change of 655.25%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation decreased to 27 million in 2024Q2 from 31 million in 2024Q1 representing a change of -12.34%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow decreased to 277 million in 2024Q2 from 561 million in 2024Q1 representing a change of -50.58%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to 162 million in 2024Q2 from 433 million in 2024Q1 representing a change of -62.69%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -116 million in 2024Q2 from -128 million in 2024Q1 representing a change of 9.67%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Deferred Income Tax: Deferred Income Tax increased to -20 million in 2024Q2 from -20 million in 2024Q1 representing a change of 0.51%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 86 million in 2024Q2 from 69 million in 2024Q1 representing a change of -224.64%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 45 in 2024Q2 from -42 million in 2024Q1 representing a change of 206.64%. This suggests that the company is less capable of collecting payments from its customers.
Dividends Paid: Dividends Paid decreased to -60 million in 2024Q2 from -60 million in 2024Q1 representing a change of -0.17%. This indicates a weaker financial position, less confidence in future prospects, and a reluctance to return value to shareholders.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 139.63 | 163.3 | -14.50 |
| net income per share | 4.8 | 14.04 | -65.82 |
| operating cash flow per share | 15.24 | 21.47 | -29.00 |
| free cash flow per share | 10.04 | 16.18 | -37.98 |
| cash per share | 6.16 | 4.72 | 30.57 |
| book value per share | 90.59 | 110.83 | -18.26 |
| tangible book value per share | -18.3 | -21.64 | 15.43 |
| shareholders equity per share | 90.41 | 110.83 | -18.42 |
| interest debt per share | 70.65 | 71.08 | -0.60 |
| market cap | 19796959000 | 18428619000 | 7.43 |
| enterprise value | 25214359001 | 24293519000 | 3.79 |
| pe ratio | 47.36 | 14.41 | 228.73 |
| price to sales ratio | 1.63 | 1.24 | 31.41 |
| pocfratio | 14.91 | 9.42 | 58.25 |
| pfcf ratio | 22.65 | 12.5 | 81.15 |
| pb ratio | 2.51 | 1.83 | 37.73 |
| ptb ratio | 2.51 | 1.83 | 37.73 |
| ev to sales | 2.07 | 1.63 | 26.96 |
| enterprise value over ebitda | 18.69 | 12.43 | 50.32 |
| ev to operating cash flow | 18.99 | 12.42 | 52.90 |
| ev to free cash flow | 28.85 | 16.48 | 75.02 |
| earnings yield | 0.02 | 0.07 | -69.58 |
| free cash flow yield | 0.04 | 0.08 | -44.80 |
| debt to equity | 0.76 | 0.62 | 21.27 |
| debt to assets | 0.36 | 0.31 | 13.99 |
| net debt to ebitda | 4.01 | 3.0 | 33.78 |
| current ratio | 1.17 | 1.5 | -22.29 |
| interest coverage | 3.64 | 9.84 | -63.05 |
| income quality | 3.5 | 1.53 | 129.24 |
| dividend yield | 0.01 | 0.01 | 21.13 |
| payout ratio | 0.61 | 0.15 | 298.18 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0.0 | 0 | NaN |
| intangibles to total assets | 0.57 | 0.6 | -5.29 |
| capex to operating cash flow | 0.34 | 0.25 | 38.66 |
| capex to revenue | 0.04 | 0.03 | 15.14 |
| capex to depreciation | 0.79 | 0.76 | 3.36 |
| stock based compensation to revenue | 0.01 | 0.01 | 34.79 |
| graham number | 98.81 | 187.12 | -47.20 |
| roic | 0.03 | 0.08 | -59.57 |
| return on tangible assets | 0.06 | 0.16 | -63.50 |
| graham net net | -74.47 | -86.67 | 14.07 |
| working capital | 540200000 | 1546500000 | -65.07 |
| tangible asset value | -1594000001 | -1971300000 | 19.14 |
| net current asset value | -5069200000 | -5433500000 | 6.70 |
| invested capital | 12936500000 | 16570600000 | -21.93 |
| average receivables | 2047999999.5 | 2487800000 | -17.68 |
| average payables | 839850000 | 736750000 | 13.99 |
| average inventory | 472600000 | 436000000 | 8.39 |
| days sales outstanding | 62.99 | 49.0 | 28.54 |
| days payables outstanding | 34.34 | 29.65 | 15.81 |
| days of inventory on hand | 19.69 | 16.37 | 20.28 |
| receivables turnover | 5.79 | 7.45 | -22.20 |
| payables turnover | 10.63 | 12.31 | -13.65 |
| inventory turnover | 18.53 | 22.29 | -16.86 |
| roe | 0.05 | 0.13 | -58.10 |
| capex per share | 5.21 | 5.29 | -1.55 |
ROE: Return on Equity (ROE) decreased to 0.05 on 2023-12-31 from 0.13 on 2022-12-31, representing a change of -58.10%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 47.36 on 2023-12-31 from 14.41 on 2022-12-31, representing a change of 228.73%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 1.17 on 2023-12-31 from 1.50 on 2022-12-31, representing a change of -22.29%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. However, it is still above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.76 on 2023-12-31 from 0.62 on 2022-12-31, representing a change of 21.27%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q2 | 2024-06-30 Q1 | Q/Q change % | |
|---|---|---|---|
| LH | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 39.07 | 38.3 | 2.02 |
| net income per share | 2.02 | 2.44 | -17.44 |
| operating cash flow per share | 3.3 | 6.67 | -50.52 |
| free cash flow per share | 1.92 | 5.15 | -62.65 |
| cash per share | 18.06 | 3.15 | 473.03 |
| book value per share | 97.45 | 95.37 | 2.17 |
| tangible book value per share | -21.88 | -18.21 | -20.14 |
| shareholders equity per share | 97.26 | 95.19 | 2.18 |
| interest debt per share | 92.49 | 71.61 | 29.16 |
| market cap | 18772320000 | 17083233000 | 9.89 |
| enterprise value | 24974120000 | 22793233000 | 9.57 |
| pe ratio | 27.72 | 20.8 | 33.25 |
| price to sales ratio | 5.72 | 5.3 | 7.84 |
| pocfratio | 67.7 | 30.45 | 122.35 |
| pfcf ratio | 116.24 | 39.46 | 194.55 |
| pb ratio | 2.3 | 2.13 | 7.68 |
| ptb ratio | 2.3 | 2.13 | 7.68 |
| ev to sales | 7.61 | 7.08 | 7.53 |
| enterprise value over ebitda | 59.11 | 49.2 | 20.15 |
| ev to operating cash flow | 90.06 | 40.62 | 121.70 |
| ev to free cash flow | 154.64 | 52.65 | 193.70 |
| earnings yield | 0.01 | 0.01 | -24.96 |
| free cash flow yield | 0.01 | 0.03 | -66.05 |
| debt to equity | 0.94 | 0.75 | 26.59 |
| debt to assets | 0.41 | 0.36 | 16.00 |
| net debt to ebitda | 14.68 | 12.32 | 19.10 |
| current ratio | 1.44 | 0.88 | 63.78 |
| interest coverage | 5.04 | 6.44 | -21.68 |
| income quality | 1.64 | 2.73 | -40.18 |
| dividend yield | 0.0 | 0.0 | -8.85 |
| payout ratio | 0.36 | 0.29 | 21.46 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.54 | 0.57 | -5.78 |
| capex to operating cash flow | 0.42 | 0.23 | 82.77 |
| capex to revenue | 0.04 | 0.04 | -11.35 |
| capex to depreciation | 0.72 | 0.82 | -12.25 |
| stock based compensation to revenue | 0.01 | 0.01 | -13.97 |
| graham number | 66.41 | 72.31 | -8.15 |
| roic | 0.01 | 0.02 | -22.09 |
| return on tangible assets | 0.02 | 0.03 | -31.26 |
| graham net net | -83.33 | -77.54 | -7.47 |
| working capital | 1497900000 | -493400000 | 403.59 |
| tangible asset value | -1837700000 | -1531400000 | -20.00 |
| net current asset value | -5517200000 | -5120200000 | -7.75 |
| invested capital | 14571000000 | 11991300000 | 21.51 |
| average receivables | 2235600000 | 2225250000 | 0.47 |
| average payables | 710750000 | 728050000 | -2.38 |
| average inventory | 462450000 | 458400000 | 0.88 |
| days sales outstanding | 61.01 | 62.77 | -2.81 |
| days payables outstanding | 25.02 | 29.05 | -13.87 |
| days of inventory on hand | 18.29 | 16.87 | 8.39 |
| receivables turnover | 1.48 | 1.43 | 2.89 |
| payables turnover | 3.6 | 3.1 | 16.11 |
| inventory turnover | 4.92 | 5.33 | -7.74 |
| roe | 0.02 | 0.03 | -19.19 |
| capex per share | 1.38 | 1.52 | -9.56 |
ROE: Return on Equity (ROE) decreased to 0.02 on 2024-09-30 Q2 from 0.03 on 2024-06-30 Q1, representing a change of -19.19%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to 27.72 on 2024-09-30 Q2 from 20.80 on 2024-06-30 Q1, representing a change of 33.25%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.44 on 2024-09-30 Q2 from 0.88 on 2024-06-30 Q1, representing a change of 63.78%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.94 on 2024-09-30 Q2 from 0.75 on 2024-06-30 Q1, representing a change of 26.59%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Positive Sentiment: Discounted Cash Flow value is 278.6 which is higher than current price 238.56, indicates the company may be undervalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-10 16:15:00
BURLINGTON, N.C. , Jan. 10, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will participate in a fireside chat at the 43rd Annual J.P.
Sentiment: Positive
Publish Date: 2025-01-09 13:11:32
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Sentiment: Positive
Publish Date: 2025-01-08 18:02:00
BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Sentiment: Positive
Publish Date: 2025-01-08 16:15:00
BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6, 2025.
Sentiment: Positive
Publish Date: 2025-01-03 12:51:11
Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
Sentiment: Positive
Publish Date: 2025-01-03 10:45:51
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Sentiment: Positive
Publish Date: 2025-01-03 08:05:42
Investors are increasingly optimistic about LH due to its focus on high-growth areas and strategic partnerships.
Sentiment: Positive
Publish Date: 2024-12-26 10:55:20
LH announces strategic agreement with Graves Gilbert Clinic for lab operations.
Sentiment: Positive
Publish Date: 2024-12-19 08:31:10
LH's new H5 bird flu test, developed in collaboration with the CDC, is now available in the United States.
Sentiment: Positive
Publish Date: 2024-12-17 08:06:21
Labcorp is set to acquire select assets of MAWD Pathology Group.
Sentiment: Negative
Publish Date: 2024-12-17 07:00:00
New test supports public health preparedness efforts and testing infrastructure amid multistate outbreak of H5 bird flu in poultry and dairy cows BURLINGTON, N.C. , Dec. 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the commercial availability of its new H5 bird flu molecular test to aid in the diagnosis of human infection with H5 bird flu.
Sentiment: Positive
Publish Date: 2024-11-29 12:16:49
For my initial coverage of Labcorp, I'm calling it a hold, and an opportunity to earn a $0.72/share quarterly dividend on the leading clinical lab company in the US. The firm shows future growth indicators through the growth of new locations and acquisitions, but also expected future patient demand for diagnostics. The company's main competitor/peer in this niche is Quest Diagnostics, and Labcorp struggles with a weak profit margin and growth in expenses.
Sentiment: Negative
Publish Date: 2024-11-26 07:52:00
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium BOSTON and BURLINGTON, N.C. , Nov. 26, 2024 /PRNewswire/ -- Outcomes4Me Inc., the developer of the first and only end-to-end, actionable cancer platform, announced today it has been selected to present the results of a biomarker awareness study, conducted with Labcorp, a global leader of innovative and comprehensive laboratory services, at the prestigious 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024.
Sentiment: Positive
Publish Date: 2024-11-20 04:23:51
Private equity firm Cinven secured a conditional approval from Italian authorities over its plan to sell a 15% stake in diagnostic service provider Synlab to laboratory operator Labcorp , a government document sent to parliament showed.
Sentiment: Positive
Publish Date: 2024-11-19 07:00:00
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C. , Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer.
Sentiment: Positive
Publish Date: 2024-11-15 08:36:09
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Sentiment: Positive
Publish Date: 2024-11-13 09:25:28
LH launches new enhancements to Global Trial Connect to streamline site workflow.
Sentiment: Positive
Publish Date: 2024-10-24 14:00:05
Labcorp Holdings Inc. (NYSE:LH ) Q3 2024 Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants Christin O'Donnell – Vice President-Investor Relations Adam Schechter – Chairman and Chief Executive Officer Glenn Eisenberg – Executive Vice President and Chief Financial Officer Conference Call Participants Ann Hynes – Mizuho Lisa Gill – JPMorgan Michael Cherny – Leerink Partners Patrick Donnelly – Citi Erin Wright – Morgan Stanley David Westenberg – Piper Sandler Jack Meehan – Nephron Research Pito Chickering – Deutsche Bank Andrew Brackmann – William Blair Kevin Caliendo – UBS Elizabeth Anderson – Evercore ISI Eric Coldwell – Baird Stephanie Davis – Barclays John Kim – Bank of America Operator Good day and thank you for standing by. Welcome to the Q3 2024 Labcorp Holdings Earnings Conference Call.
Sentiment: Positive
Publish Date: 2024-10-24 12:16:10
Labcorp beats on earnings and revenues in the third quarter, entering the fourth half of 2024 with robust momentum.
Sentiment: Positive
Publish Date: 2024-10-24 11:35:27
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
